



MEETING

“VI Neurotoxicity Society Meeting: Mechanisms of neurodegenerative disorders” will take place in Valdivia, Chile, during March 21-24, 2013.
Webpage: <http://nts.med.uchile.cl/NS/valdivia/>

Place: Valdivia

The meeting will take place in Valdivia that is located 700 km south of Santiago. Valdivia, the City of Rivers, was founded by Pedro de Valdivia in 1522. Taking advantage of the harbor, the rivers and the strategic location for ships rounding Cape Horn or navigating the Strait of Magellan on the route to Lima and the Viceroyalty of Peru, the founding fathers were pleased to find the area rich in timber and gold. Valdivia became an important port known as the La Perla del Sur, Southern Pearl, and an enviable asset of the Spanish crown. To protect Valdivia and Bahía de Corral, Spanish forces began building a fort in 1645, constructing the castles at Mancera, Corral, Niebla, Amargos and Cruces, and among others, the forts of San Carlos and El Molino. Valdivia became the most heavily fortified port in the Spanish colonies.

Airport: The airport I located in Valdivia and is very close to the hotels (<http://www.aeropuertovaldivia.com/english/publish/>)

Website: nts.med.uchile.cl/valdivia

Participants: The meeting is open to all participants.

Official language: English

Meeting composition: conferences, presentations, and poster sessions.

Posters: 130 x 130 cm should be set up March 21. The posters will be divided in different sessions and the author of the poster should present the poster during the guided poster session.

Guided Poster Sessions: The chair of the poster session will lead a guided tour around the poster with all the session participants and other participants.

Secretariat e- mail: jsegura@med.uchile.cl

Registration: The registration will be open from August 2012 in NTS webpage:

Academic Participants: 400 US\$ (late registration 500 US\$)

Participants from Pharmaceutical Industry: 600 US\$ (late registration 800 US\$)

Member of Neurotoxicity Society: 300 US\$

Students 50 US\$ (late registration 70 US\$).

Students Members of Neurotoxicity Society: (25 US\$).

Social program

Welcome reception (March 20, 20.00 h.)

Gala Dinner (March 23, 20.30 h)

River tour around Valdivia including lunch (price will be announced soon) (March 22, afternoon).

Deadlines

Registration: January 15, 2013

Hotel booking: February 21, 2013

Abstracts submission: January 15, 2013

Late registration until March 21, 2013

Manuscript (invited speakers) March 21, 2013

Publication

The abstracts book and invited speakers manuscript will be published in NTS official journal “Neurotoxicity Research”

<http://www.springer.com/biomed/neuroscience/journal/12640>

Exhibitions

Commercial exhibitions of Pharmaceutical Companies will be close to the lecture hall and the same place that coffee will be served. This is a very good possibility to present yours products to a wide group composed of basic and clinical scientist. The rate for renting space is 2000 US\$.

Accommodation:

Hotel Diego de Almagro

Hotel strategically located in the Ribera del Rio Street and steps of the center, offers everything for the convenience of business executive and tourists. More information can be found in <http://www.dahoteles.com/da/seleccion.php?hotel=21&lang=es>

	One night	5 nights
Single	49385	246925
Double	59024	295120
Triple	66640	399840

The prices included the taxes (19%) and there is a law for international tourist in Chile that they do not pay taxes if they request this benefit but they must pay in USD. One USD is about 500 pesos but this change all the time up or down depending of world economy and the hotel have a special value for the USD that is used when you pay as international tourist.

PRELIMINARY PROGRAM

March 20, Place: CECS, Valdivia

PLENARY LECTURE

20:00 Inaugural ceremony

21:00 Reception

March 21. Place Dreams hotel

SYMPOSIUM 1: ISN-SYMPOSIUM



Neurochemical mechanism in neurodegeneration in Parkinson's disease

Neurochemical mechanism in neurodegeneration in Parkinson's disease

8:30. Moussa Youdim, (Israel) Neurorestorative Multi Target Anti

Parkinson drugs; An Alternative to Stem Cells Therapy

9:00. Elaine A. Del Bel (Brazil) Levodopa-induced dyskinesia in hemiparkinsonian rats: modulation of the cellular changes in the striatum by nitric oxide synthase inhibition

9:30. Rosario Moratalla, (Spain) Synaptic plasticity of denervated striatal neurons in Parkinson disease

10:00. Micaela Morelli (Italia) "Adenosinergic target in the control of motor behavior and neurotoxicity in Parkinson's disease"

10:30. Cofee

11:00. Rolf Heumann, (Germany) Intracellular neuronal signalling mechanisms in Parkinson disease models.

11:30. Wojciech Danysz, (Germany) mGluR5 receptors in Parkinson's disease: perspectives and recent findings

12:00. Juan Segura-Aguilar (Chile) Aminochrome a new preclinical model for Parkinson's disease

12:30. Irmgard Paris (Chile) Studies on the role of aminochrome on cytoskeleton

13:00 Luigi Zecca (Italy) Neuromelanin organelles and autophagy in brain aging

13:30. Lunch

SYMPOSIUM 2: Protein aggregation and autophagy

15:00. Natalia Ninkina, (UK) Selective effect of gamma-carbolines on various types of proteinopathies (AD, PD, ALS)

15:30. Anthony R. White (Australia) Kinase control of protein aggregation and neurotoxicity in motor neuron

16:00. Claudio Hetz, (Chile) Protein folding stress in neurodegenerative diseases: A look into the ER

16:30. Benjamin Dehay, (France) Loss of PARK9/ATP13A2 function induces cell death through general lysosomal deficiency: implications for Parkinson's disease

17:00. Fuentes Jose Manuel (Spain) The LRRK2 G2019S mutant exacerbates basal autophagy and sensitises cells against a neurotoxin related to Parkinson's disease

March 22. Place Dreams hotel

SYMPOSIUM 3: Neurodegeneration & Alzheimer

9:00.

9:30. Xin-Fu Zhou (Australia) Roles of sortilin in APP trafficking and processing.

10:00. Harry Steinbusch, (The Netherlands) Morphological basis of neural plasticity in normal animals and animals with neurodegenerative and neuroinflammatory diseases. Possible mechanistic interrelationships between depression – Alzheimer disease.

10:30. Coofee

11:00. Chris Parsons (Germany) A β as a target for drug development for Alzheimer's disease

11:30. Rommy Von Bernhardt (Chile) Participation of Scavenger Receptor A in the inflammatory activation of glial cells: a potential target for therapeutic intervention in Alzheimer's disease

14:00-19:30. Tour around Valdivia river (Lunch)

March 23. Place Dreams hotel

SYMPOSIUM 4: Neurodegeneration

8:30. Andrew Tasker, (Canada) Molecular determinants of delayed-onset neurological disease originating during brain development

9:00. Rainer K.W. Schwarting (Germany) Effects of neurotoxic lesions on sequential learning and performance in rats

9:30. Dora Reglodi, (Hungary) Excitotoxicity in the rat retina and possible therapeutic interventions

10:00. Cornelis J. Van der Schyf, (USA) Axonopathy in Retinal Neurodegeneration: Seeing past the eye",

10:30. Coofee

SYMPOSIUM 5: Neurodegeneration in ALS, HIV & drug abuse

11:00. Italo Mocchetti (USA) Axonal degeneration, a new mechanism of HIV neurotoxicity

11:30. Peter S. Spencer, (USA) Western Pacific ALS-PDC: the Rosetta Stone of Neurodegenerative Diseases."

12:00. Richelle A. Hemendinger (USA) Neurotoxins in Amyotrophic Lateral Sclerosis".

12:30. Jean-Lud Cadet, Transcriptional and epigenetic effects of chronic methamphetamine administration.

13:00. Pablo Caviedes (Chile) Role of over expressed Rcan1 in altered voltage dependent Calcium currents in a neuronal cell line derived from the Ts16 mouse model of Down syndrome.

13:30. Lunch

SYMPOSIUM 7: Neuroprotection

15:00. Julie Andersen, (USA) natural products as novel therapeutics for neurodegenerative disease

15:30. Lucyna Antkiewicz (Poland) 1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: a new vistas of therapeutic application"

16:00. Yousef Tizabi, (USA) novel insights into neuroprotection by natural and synthetic compounds

16:30. Coofee

17:00. Justine Renaud (Canada) Protective effects of natural anti-oxidant molecules in neurodegenerative mechanisms

17:30. Nibaldo Inestrosa (Chile) Role of Natural Protection in Synapse Neuroprotection.

March 24. Place Dreams hotel

SYMPOSIUM 8: Neurodegeneration in perinatal models

8:30. Miriam Virgolini, (Argentina) Participation of brain catalase in the motivational properties of ethanol in perinatally low-level lead exposed rats,"

9:00. Marta Antonelli, (Argentina) Gestational stress impairs the neuroendocrine response in male offsprings".

9:30. Mario Herrera-Marschitz, (Chile) Asphyxia at birth increases the vulnerability to postnatal metabolic insults

10:00. Coofee

SYMPOSIUM 9: Neurotoxins and models

10:30. Peter Jener, (UK) Using toxins to study neurodegenerative disease'.

11:00. Vladimir Buchman, (UK) New models for studying molecular and cellular mechanisms involved in pathogenesis of movement disorders

11:30. Gilles Guillemain, (Australia) Quinolinic acid the inescapable neurotoxin

12:00. Andreas Támas, (Hungary) Examination of kanamycin induced ototoxicity in wild type and PACAP KO animals.

12:30. Richard Kostrzewa (USA) The Dopamine D2 Agonist Quinpirole as a non-Neurodegenerative Neurotoxin

13:00. Lunch

SYMPOSIUM 10: Neurodegeneration, glia cells and metals

14:30. Arne Schousboe, (Denmark) Adrenergic Regulation of Astrocytic Energy Metabolism and its Role in Glutamatergic Neurotransmission".

15:00. James O Olopade (Nigeria) Gene expression alteration in oligodendrocytes exposed to Vanadium

15:30. Silvia Costas, (Brazil) Understanding the role of astrocytes on metabolism and neurotoxicity of pyrrolizidine alkaloid monocrotaline, the main toxin from *Crotalaria retusa*

16:00. Coofee

16:30. Jean Harry (USA) Dissecting the M1/M2 responses associated with resident microglia activation.

17:00. Rita Raisman-Vozari (France) Effect of chemicals possessing a neurotrophin-like activity on dopaminergic neurons

17:30. Maria Trinidad Herrero (Spain) Inflammation, glyapase formation and inhibition of microglial motility in parkinsonism.

This Meeting is supported by:



IUBMB

ISN

IBRO-LARC

The Company of Biologists

Springer



This meeting is endorsed by  The Movement Disorder Society